SMARCA4 and neoplasm of thorax: In a study by Shinno et al. on ICIs in SMARCA4‐deficient thoracic tumors, the response rate to ICIs was 42%, and the progression‐free survival time with ICIs was significantly longer with the first‐line regimen than with the second‐line or later treatment; additionally, TMB could be used to predict patients who would benefit from ICIs.5